Two Sigma Advisers LP boosted its holdings in shares of Versartis (NASDAQ:VSAR) by 63.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 155,700 shares of the biopharmaceutical company’s stock after buying an additional 60,700 shares during the quarter. Two Sigma Advisers LP’s holdings in Versartis were worth $343,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Ascend Capital LLC grew its holdings in Versartis by 18.5% during the 4th quarter. Ascend Capital LLC now owns 623,614 shares of the biopharmaceutical company’s stock worth $1,371,000 after acquiring an additional 97,184 shares during the period. Virtu Financial LLC grew its holdings in Versartis by 713.6% during the 4th quarter. Virtu Financial LLC now owns 163,585 shares of the biopharmaceutical company’s stock worth $360,000 after acquiring an additional 143,478 shares during the period. Guggenheim Capital LLC acquired a new stake in Versartis during the 4th quarter worth $1,989,000. Deutsche Bank AG grew its holdings in Versartis by 90.0% during the 4th quarter. Deutsche Bank AG now owns 82,299 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 38,975 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Versartis by 362.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 295,902 shares of the biopharmaceutical company’s stock worth $651,000 after acquiring an additional 231,860 shares during the period. 48.47% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have commented on VSAR. ValuEngine raised shares of Versartis from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Canaccord Genuity lowered shares of Versartis from a “buy” rating to a “hold” rating and lowered their target price for the stock from $9.00 to $5.00 in a report on Friday, March 2nd. Finally, Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a report on Sunday, January 21st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. Versartis has a consensus rating of “Hold” and a consensus price target of $5.13.
Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $1.78. The firm had revenue of $0.04 million during the quarter. equities analysts expect that Versartis will post -3.15 EPS for the current fiscal year.
In other news, insider Jay Shepard sold 14,446 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $1.80, for a total value of $26,002.80. Following the completion of the transaction, the insider now owns 602,298 shares of the company’s stock, valued at approximately $1,084,136.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 25,745 shares of company stock valued at $46,124 in the last three months. 10.90% of the stock is owned by company insiders.
WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3381452/two-sigma-advisers-lp-has-343000-holdings-in-versartis-vsar.html.
Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis (NASDAQ:VSAR).
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.